8-K Announcements
6Material company update
Feb 26, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Nov 6, 2025·SEC
Tectonic Therapeutic, Inc.(TECX)Earnings, Financials & Key Ratios
TECX•NASDAQ
$29.02
$543M mkt cap·Price updated May 6, 2026
AboutTectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.Show more
- Revenue$0
- EBITDA-$56M-30.6%
- Net Income-$58M-35.4%
- EPS (Diluted)-3.93+65.9%
- ROE-206.56%
- Debt/Equity0.02
- Interest Coverage-542.20-84.6%
TECX Key Insights
Tectonic Therapeutic, Inc. (TECX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 85 (top 15%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TECX Price & Volume
Tectonic Therapeutic, Inc. (TECX) stock price & volume — 10-year historical chart
Loading chart...
TECX Growth Metrics
Tectonic Therapeutic, Inc. (TECX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-25.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM60.29%
Return on Capital
10 Years-124.19%
5 Years-96.12%
3 Years-138.36%
Last Year-82.99%
TECX Recent Earnings
Tectonic Therapeutic, Inc. (TECX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q1 2026Latest
Feb 26, 2026EPS
$1.03
Est $1.11
+7.2%
Revenue
—
Q4 2025
Nov 6, 2025EPS
$1.02
Est $1.05
+2.9%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$1.07
Est $0.98
-9.2%
Revenue
—
Q2 2025
May 8, 2025EPS
$0.93
Est $1.10
+15.5%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $1.03vs $1.11+7.2% | — |
| Q4 2025 | Nov 6, 2025 | $1.02vs $1.05+2.9% | — |
| Q3 2025 | Aug 7, 2025 | $1.07vs $0.98-9.2% | — |
| Q2 2025 | May 8, 2025 | $0.93vs $1.10+15.5% | — |
Based on last 12 quarters of dataView full earnings history →
TECX Peer Comparison
Tectonic Therapeutic, Inc. (TECX) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 ALKS | 5.89B | 35.32 | 24.70 | -5.25% | 9.78% | 8.82% | 0.04 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 |
Compare TECX vs Peers
Tectonic Therapeutic, Inc. (TECX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TECX Income Statement
Tectonic Therapeutic, Inc. (TECX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 45K | 380K | 850K | 1.21M | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | -45K▲ 0% | -380K▼ 744.4% | -850K▼ 123.7% | -1.21M▼ 42.0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | -744.44% | -123.68% | -42% | 100% | - | - | - | - |
| Operating Expenses | 4.63M | 18.34M | 45.86M | 74.96M | 119.02M | 15.61M | 32.83M | 44.65M | 58.02M | 76.51M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.96M | 3.15M | 10.77M | 19.98M | 32.99M | 4.63M | 7.18M | 7.68M | 16.65M | 20.21M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 2.66M | 15.19M | 35.09M | 54.97M | 86.03M | 10.98M | 25.65M | 36.97M | 41.36M | 56.3M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -4.63M▲ 0% | -18.39M▼ 297.5% | -46.24M▼ 151.5% | -75.81M▼ 63.9% | -120.23M▼ 58.6% | -15.61M▲ 87.0% | -32.83M▼ 110.3% | -44.65M▼ 36.0% | -58.02M▼ 29.9% | -76.51M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -297.54% | -151.51% | -63.94% | -58.59% | 87.02% | -110.31% | -36% | -29.94% | - |
| EBITDA | -4.66M | -18.34M | -45.86M | -74.96M | -119.02M | -15.25M | -31.82M | -43.17M | -56.37M | -72.43M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -293.25% | -150.06% | -63.44% | -58.78% | 87.19% | -108.74% | -35.65% | -30.58% | -39.59% |
| D&A (Non-Cash Add-back) | 0 | 45K | 380K | 850K | 1.21M | 364K | 1.01M | 1.48M | 1.65M | 1.21M |
| EBIT | -4.66M | -18.65M | -46.36M | -72.97M | -119.71M | -8.48M | -32.04M | -42.67M | -57.88M | -66.25M |
| Net Interest Income | 0 | 0 | 0 | 2.93M | 719K | -224K | 5K | 429K | 4.15M | 10.39M |
| Interest Income | 6K | 57K | 1.73M | 2.93M | 719K | 0 | 149K | 581K | 4.26M | 10.47M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 224K | 144K | 152K | 107K | 73K |
| Other Income/Expense | -39K | -262K | -118K | 2.84M | 516K | 6.68M | 650K | 1.82M | 33K | 10.19M |
| Pretax Income | -4.66M▲ 0% | -18.65M▼ 299.8% | -46.36M▼ 148.6% | -72.97M▼ 57.4% | -119.71M▼ 64.1% | -8.93M▲ 92.5% | -32.18M▼ 260.5% | -42.82M▼ 33.1% | -57.98M▼ 35.4% | -66.32M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 976K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -1.47% |
| Net Income | -4.66M▲ 0% | -18.65M▼ 299.8% | -46.36M▼ 148.6% | -72.97M▼ 57.4% | -119.71M▼ 64.1% | -8.93M▲ 92.5% | -32.18M▼ 260.5% | -42.82M▼ 33.1% | -57.98M▼ 35.4% | -67.3M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -299.83% | -148.61% | -57.38% | -64.07% | 92.54% | -260.48% | -33.07% | -35.4% | -25.84% |
| Net Income (Continuing) | -4.66M | -18.65M | -46.36M | -72.97M | -119.71M | -8.93M | -32.18M | -42.82M | -57.98M | -67.3M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.34▲ 0% | -9.35▼ 299.6% | -23.41▼ 150.4% | -31.92▼ 36.4% | -39.68▼ 24.3% | -33.36▲ 15.9% | -29.05▲ 12.9% | -11.53▲ 60.3% | -3.93▲ 65.9% | -3.60▲ 0% |
| EPS Growth % | - | -299.57% | -150.37% | -36.35% | -24.31% | 15.93% | 12.92% | 60.31% | 65.92% | 60.29% |
| EPS (Basic) | -2.34 | -9.35 | -23.41 | -31.92 | -39.68 | -33.36 | -29.05 | -11.59 | -3.93 | - |
| Diluted Shares Outstanding | 1.99M | 1.99M | 1.98M | 2.29M | 3.02M | 3.57M | 3.64M | 3.71M | 14.77M | 18.71M |
| Basic Shares Outstanding | 1.99M | 1.99M | 1.98M | 2.29M | 3.02M | 3.57M | 3.64M | 3.69M | 14.77M | 18.71M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TECX Balance Sheet
Tectonic Therapeutic, Inc. (TECX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.38M | 6.31M | 130.02M | 195.7M | 267.24M | 28.62M | 37.04M | 30.88M | 146.86M | 273.24M |
| Cash & Short-Term Investments | 5.36M | 5.96M | 126.3M | 187.04M | 259.68M | 28.06M | 35.97M | 28.77M | 141.24M | 268.44M |
| Cash Only | 5.36M | 5.96M | 126.3M | 187.04M | 259.68M | 28.06M | 35.97M | 28.77M | 141.24M | 268.44M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 1.54M | 2.14M | 2.56M | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 4K | 60K | 795K | 620K | 271K | 557K | 1.08M | 2.12M | 5.62M | 4.81M |
| Total Non-Current Assets | 24K | 714K | 3.46M | 4.81M | 3.99M | 4.26M | 10.17M | 8.52M | 6.05M | 3.76M |
| Property, Plant & Equipment | 0 | 349K | 2.63M | 3.7M | 3.06M | 3.66M | 9.55M | 7.23M | 5.3M | 2.68M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 24K | 24K | 492K | 492K | 492K | 0 | 0 | 0 | 587K | 0 |
| Other Non-Current Assets | 0 | 341K | 333K | 625K | 436K | 599K | 613K | 1.29M | 156K | 3.42M |
| Total Assets | 5.4M▲ 0% | 7.02M▲ 30.0% | 133.48M▲ 1800.9% | 200.51M▲ 50.2% | 271.23M▲ 35.3% | 32.88M▼ 87.9% | 47.21M▲ 43.6% | 39.4M▼ 16.5% | 152.91M▲ 288.1% | 277M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 30.04% | 1800.87% | 50.22% | 35.27% | -87.88% | 43.59% | -16.54% | 288.09% | 645.48% |
| Total Current Liabilities | 891K | 2.63M | 10.61M | 14.02M | 16.61M | 4.12M | 7.84M | 40.89M | 11.61M | 9.37M |
| Accounts Payable | 340K | 527K | 2.78M | 3.95M | 2.68M | 1.81M | 574K | 409K | 976K | 1.49M |
| Days Payables Outstanding | - | 4.27K | 2.67K | 1.7K | 811.04 | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.14M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 177K | 1.3M | 5.21M | 7.04M | 7.53M | 1.76M | 2.66M | 33.37M | 3.58M | 6.75M |
| Current Ratio | 6.03x | 2.40x | 12.26x | 13.96x | 16.09x | 6.95x | 4.73x | 0.76x | 12.65x | 12.65x |
| Quick Ratio | 6.03x | 2.40x | 12.26x | 13.96x | 16.09x | 6.95x | 4.73x | 0.76x | 12.65x | 12.65x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 88K | 1.03M | 689K | 484K | 276K | 43.72M | 85.03M | 83.15M | 519K | 100K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 700K | 4.34M | 2.52M | 519K | 988K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 88K | 1.03M | 689K | 484K | 276K | 43.02M | 80.68M | 80.63M | 0 | 0 |
| Total Liabilities | 979K | 3.66M | 11.29M | 14.5M | 16.89M | 47.84M | 92.86M | 124.03M | 12.13M | 9.47M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 1.05M | 5.79M | 4.34M | 3.3M | 1.24M |
| Net Debt | -5.36M | -5.96M | -126.3M | -187.04M | -259.68M | -27.01M | -30.17M | -24.43M | -137.94M | -267.2M |
| Debt / Equity | - | - | - | - | - | - | - | - | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 3.69x |
| Interest Coverage | - | - | - | - | - | -69.69x | -227.99x | -293.74x | -542.20x | -907.52x |
| Total Equity | 4.42M▲ 0% | 3.37M▼ 23.9% | 122.18M▲ 3531.0% | 186.01M▲ 52.2% | 254.34M▲ 36.7% | -14.96M▼ 105.9% | -45.65M▼ 205.2% | -84.64M▼ 85.4% | 140.78M▲ 266.3% | 267.53M▲ 0% |
| Equity Growth % | - | -23.89% | 3531.03% | 52.24% | 36.73% | -105.88% | -205.17% | -85.39% | 266.33% | 653.68% |
| Book Value per Share | 2.22 | 1.69 | 61.68 | 81.37 | 84.30 | -4.19 | -12.53 | -22.79 | 9.53 | 14.30 |
| Total Shareholders' Equity | 4.42M | 3.37M | 122.18M | 186.01M | 254.34M | -14.96M | -45.65M | -84.64M | 140.78M | 267.53M |
| Common Stock | 1K | 1K | 2K | 3K | 4K | 0 | 0 | 0 | 2K | 2K |
| Retained Earnings | -4.83M | -23.48M | -71.74M | -144.7M | -264.42M | -15.6M | -47.78M | -90.6M | -148.59M | -203.51M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1K | -1K | 0 | 0 | 0 | 0 | 0 | -11K | 9K | -75K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TECX Cash Flow Statement
Tectonic Therapeutic, Inc. (TECX) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -3.31M | -16.38M | -37.65M | -67.67M | -98.8M | -12.45M | -97.21M | -40.68M | -59.08M | -59.08M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -394.33% | -129.81% | -79.74% | -46.01% | 87.4% | -680.54% | 58.15% | -45.23% | -86.25% |
| Net Income | -4.66M | -18.65M | -46.36M | -72.97M | -119.71M | -8.93M | -32.18K | -42.82M | -57.98M | -67.3M |
| Depreciation & Amortization | 0 | 45K | 380K | 850K | 1.21M | 364K | 1.01K | 1.48M | 1.65M | 1.91M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 639K | 1.12K | 1.12M | 3.49M | 10.73M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 463K | 549K | 2.9M | 6.63M | 15.46M | -6.45M | -89.78M | 127K | 4.04M | 14.7M |
| Working Capital Changes | 710K | 1.59M | 4.18M | -2.18M | 4.24M | 1.92M | -7.4M | -584K | -10.28M | -6.57M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 177K | 176K | 2.02M | 1.03M | -881K | 1.45M | -3.1M | -165K | -1.42M | -978K |
| Cash from Investing | -24K | -383K | -1.83M | -1.58M | -1.18M | -2.12M | -267K | -279K | -156K | -141K |
| Capital Expenditures | 0 | -383K | -1.83M | -1.58M | -1.18M | -2.12M | -267K | -279K | -156K | -238K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 55K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42K |
| Cash from Financing | 8.7M | 17.37M | 160.29M | 129.99M | 172.62M | 41.42M | 262K | 33.75M | 171.71M | 172.43M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 3.61M | -393K | -499K | -475K | -477K |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 262K | 1000K | 1000K | 899K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 8.7M | -44K | 0 | 0 | 0 | 2K | 393K | 121K | 77.59M | -1.29M |
| Net Change in Cash | 5.36M▲ 0% | 606K▼ 88.7% | 120.34M▲ 19757.9% | 60.74M▼ 49.5% | 72.64M▲ 19.6% | 26.84M▼ 63.0% | -96.72M▼ 460.3% | -7.2M▲ 92.6% | 112.47M▲ 1662.7% | 109.83M▲ 0% |
| Free Cash Flow | -3.31M▲ 0% | -16.77M▼ 405.9% | -39.48M▼ 135.5% | -69.25M▼ 75.4% | -99.98M▼ 44.4% | -14.58M▲ 85.4% | -97.47M▼ 568.7% | -40.96M▲ 58.0% | -59.24M▼ 44.6% | -62.68M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -405.88% | -135.49% | -75.41% | -44.37% | 85.42% | -568.74% | 57.98% | -44.62% | -15.81% |
| FCF per Share | -1.66 | -8.40 | -19.93 | -30.29 | -33.14 | -4.08 | -26.74 | -11.03 | -4.01 | -4.01 |
| FCF Conversion (FCF/Net Income) | 0.71x | 0.88x | 0.81x | 0.93x | 0.83x | 1.40x | 3.02x | 0.95x | 1.02x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 152K | 107K | 48K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TECX Key Ratios
Tectonic Therapeutic, Inc. (TECX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -479.01% | -73.85% | -47.35% | -54.37% | -7.46% | - | - | -206.56% | -25.16% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | 21272.75% |
| Debt / Equity | - | - | - | - | - | - | - | 0.02x | 0.02x |
| Interest Coverage | - | - | - | - | -69.69x | -227.99x | -293.74x | -542.20x | -907.52x |
| FCF Conversion | 0.88x | 0.81x | 0.93x | 0.83x | 1.40x | 3.02x | 0.95x | 1.02x | 0.93x |
TECX SEC Filings & Documents
Tectonic Therapeutic, Inc. (TECX) SEC filings — annual & quarterly reports (10-K, 10-Q)
TECX Frequently Asked Questions
Tectonic Therapeutic, Inc. (TECX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tectonic Therapeutic, Inc. (TECX) grew revenue by 0.0% over the past year. Growth has been modest.
Tectonic Therapeutic, Inc. (TECX) reported a net loss of $67.3M for fiscal year 2024.
Dividend & Returns
Tectonic Therapeutic, Inc. (TECX) has a return on equity (ROE) of -206.6%. Negative ROE indicates the company is unprofitable.
Tectonic Therapeutic, Inc. (TECX) had negative free cash flow of $62.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More TECX
Tectonic Therapeutic, Inc. (TECX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates